PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15676214-0	2005	Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.	Cytarabine	65-85	CD33 molecule	Homo sapiens	5-9	
15676214-5	2005	RESULTS: CD33 ligation induced a significant increase in ara-C- or IDA- but not VP-16-or Bryostatin-mediated inhibition of proliferation and colony formation.	Cytarabine	57-62	CD33 molecule	Homo sapiens	9-13	
15676214-8	2005	Combined treatment of AML cells by ara-C or IDA with anti-CD33 mAb resulted in higher levels of SHP-1 phosphorylation.	Cytarabine	35-40	CD33 molecule	Homo sapiens	58-62	
15676214-10	2005	CONCLUSION: These data suggest that combined incubation of leukemia cells with anti-CD33 mAb and ara-C or IDA, but not VP-16 or Bryostatin, independently triggers similar events in the downstream signaling cascade, and therefore leads to additive antiproliferative effects and enhanced cytotoxicity.	Cytarabine	97-102	CD33 molecule	Homo sapiens	84-88	
34181204-1	2021	BACKGROUND AND OBJECTIVE: The phase III ALFA-0701 study demonstrated the efficacy and safety of gemtuzumab ozogamicin (GO) versus standard of care (SOC) chemotherapy (daunorubicin and cytarabine) for the treatment of adult patients with de novo CD33+ acute myeloid leukaemia (AML).	Cytarabine	184-194	CD33 molecule	Homo sapiens	245-249	
18854573-0	2008	Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.	Cytarabine	68-78	CD33 molecule	Homo sapiens	114-118	
34572794-3	2021	In the last years, the therapeutic options have rapidly changed, with the approval of innovative compounds that provide new opportunities, together with new challenges for clinicians: among them, on 1 September, 2017 the Food and Drug Administration granted approval for Gemtuzumab Ozogamicin (GO) in combination with daunorubicin and cytarabine for the treatment of adult patients affected by newly diagnosed CD33+ AML.	Cytarabine	335-345	CD33 molecule	Homo sapiens	410-414	
22584460-0	2013	Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.	Cytarabine	145-155	CD33 molecule	Homo sapiens	55-59	
20858843-11	2010	Biodistribution and pharmacokinetic studies suggested that saturation of available CD33 sites by (213)Bi-lintuzumab was achieved after partial cytoreduction with cytarabine.	Cytarabine	162-172	CD33 molecule	Homo sapiens	83-87	
19446624-7	2009	Finally, the pH-sensitive ILs-CD33 formulation exhibited the highest cytotoxicity against HL60 cells, confirming the role of the NIPAM copolymer in promoting the escape of intact ara-C in the endosomes.	Cytarabine	179-184	CD33 molecule	Homo sapiens	30-34